Table 6. Abbott anti-SARS-CoV-2 Architect and Alinity assays performance compared with in-house Elisa reported by clinical presentation (severity).
| Abbott SARS-CoV2 Architect Assay | Abbott SARS-CoV2 Alinity Assay | |||
|---|---|---|---|---|
| Clinical presentation | 0–14 days (n = 23) | >14 days (n = 85) | 0–14 days (n = 21) | >14 days (n = 82) |
| Asymptomatic | NAa | 90.9% | NAa | 90.9% |
| Mild | NAa | 85.7% | NAa | 85.7% |
| Moderate | 80% | 94.4% | 88.8% | 94.3% |
| Severe | 100% | 92.3% | 88.8% | 90.9% |
NAa- not available–Denotes that the number of patients were too small to give a true reflection of assay performance by clinical presentation compared to in-house Elisa